Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review

Alberto J. Montero, Betsy Adams, C. Marcela Diaz-Montero, Stefan Glück

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane®) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol®) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.

Original languageEnglish
Pages (from-to)329-334
Number of pages6
JournalExpert Review of Clinical Pharmacology
Volume4
Issue number3
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Paclitaxel
Breast Neoplasms
Nanoparticles
Cytotoxins
Biological Factors
Adjuvant Chemotherapy
Combination Drug Therapy
Therapeutics
Recurrence
130-nm albumin-bound paclitaxel
Albumin-Bound Paclitaxel

Keywords

  • metastatic breast cancer
  • nab-paclitaxel
  • taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nab-paclitaxel in the treatment of metastatic breast cancer : A comprehensive review. / Montero, Alberto J.; Adams, Betsy; Diaz-Montero, C. Marcela; Glück, Stefan.

In: Expert Review of Clinical Pharmacology, Vol. 4, No. 3, 01.05.2011, p. 329-334.

Research output: Contribution to journalArticle

Montero, Alberto J. ; Adams, Betsy ; Diaz-Montero, C. Marcela ; Glück, Stefan. / Nab-paclitaxel in the treatment of metastatic breast cancer : A comprehensive review. In: Expert Review of Clinical Pharmacology. 2011 ; Vol. 4, No. 3. pp. 329-334.
@article{be08d401611d4975b839fe2368c7455c,
title = "Nab-paclitaxel in the treatment of metastatic breast cancer: A comprehensive review",
abstract = "The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane{\circledR}) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol{\circledR}) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.",
keywords = "metastatic breast cancer, nab-paclitaxel, taxanes",
author = "Montero, {Alberto J.} and Betsy Adams and Diaz-Montero, {C. Marcela} and Stefan Gl{\"u}ck",
year = "2011",
month = "5",
day = "1",
doi = "10.1586/ecp.11.7",
language = "English",
volume = "4",
pages = "329--334",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Nab-paclitaxel in the treatment of metastatic breast cancer

T2 - A comprehensive review

AU - Montero, Alberto J.

AU - Adams, Betsy

AU - Diaz-Montero, C. Marcela

AU - Glück, Stefan

PY - 2011/5/1

Y1 - 2011/5/1

N2 - The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane®) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol®) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.

AB - The novel paclitaxel formulation (nanoparticle albumin-bound [nab] paclitaxel (Abraxane®) has recently been approved by the US FDA for treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months after adjuvant chemotherapy. Apart from its superior efficacy, as demonstrated in the pivotal Phase III study, less toxicity compared with the traditional solvent-containing paclitaxel (Taxol®) seems to contribute to its favorable therapeutic index. While approved as a single agent, nab-paclitaxel may prove more effective in combination with either biologic agents and/or other cytotoxic chemotherapeutic agents, as summarized in this article.

KW - metastatic breast cancer

KW - nab-paclitaxel

KW - taxanes

UR - http://www.scopus.com/inward/record.url?scp=79955949716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955949716&partnerID=8YFLogxK

U2 - 10.1586/ecp.11.7

DO - 10.1586/ecp.11.7

M3 - Article

C2 - 22114779

AN - SCOPUS:79955949716

VL - 4

SP - 329

EP - 334

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -